• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Thursday, August 18, 2022
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Trial may uncover new diagnostics and treatment option for cardiovascular disease

Bioengineer by Bioengineer
December 18, 2018
in Health
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Arterez, LLC


DETROIT – Forty-two percent of all deaths in the United States are related to cardiovascular disease (CVD). According to the Global Cardiovascular Drugs Market Forecast, by 2030 the number of deaths from CVD will rise to 23.6 million per year in the U.S. alone. Along with increased deaths, spending on drugs to treat CVD as well as related hospital stays, home health care and lost productivity will also rise.

A Wayne State University research team led by Phillip Levy, M.D., MPH, FACEP, FAHA, FACC, the Edward S. Thomas Endowed Professor and Associate Chair for Research in the Department of Emergency Medicine, and assistant vice president for Translational Science and Clinical Research Innovation, in collaboration with Arterez, LLC, a Michigan-based biopharmaceutical company, has commenced a clinical study to identify the “fingerprint” and diagnostic accuracy of Arterez’ seven patent-pending glycocalyx biomarkers in relation to arterial disease, specifically hypertension and heart failure, the first two of several diagnostic panels WSU and Arterez may collaborate on.

Atherosclerotic plaques that form in arteries lead to coronary heart disease, myocardial infarction, stroke and peripheral arterial disease. Formation of these plaques includes the accumulated injury to the lining of the arteries themselves, known as the endothelial glycocalyx. In research and clinical practice, tremendous emphasis has been placed on controlling cholesterol, with limited attention directed toward the repair and maintenance of the endothelial and related factors Arterez has identified as being critical to achieve prevention and possibly a cure.

Arterez, led by Dr. Joe Tunac, Ph.D., a medical scientist with more than 40 years of drug development experience across the spectrum of disease — including Avermectin, a 2015 Nobel prize-winning drug — has embarked on a journey to discover novel methods of predicting, preventing and curing various diseases within the CVD family including repairing injury to, and subsequently maintaining, the arterial lining by focusing on a set of proteins that make up the glycocalyx. These proteins can be quantified and formulate the basis of an entirely new biomarker pathway to identify individuals at risk for or already suffering from arterial injury who may be amenable to targeted therapeutic intervention.

In addition to the biomarkers, Arterez has discovered a first-in-class, triple-compound oral therapy called Embotricin that proved nontoxic in 28-day studies. In preliminary studies, Embotricin successfully prevented and reversed arterial plaque. Arterez and Wayne State have also begun discussions toward development of Institutional Review Board (IRB) in-human research studies focused on the safety and efficacy of Embotricin, enabling commercialization of a completely novel therapeutic option for management of CVD.

“We are delighted to partner with Arterez on this exciting line of research,” said Levy. “The glycocalyx represents the next area of emphasis in the ongoing battle against CVD, and our collaboration with Arterez represents the leading edge of this effort.”

“Dr. Levy and the Wayne State research team are an ideal partner for Arterez given their knowledgeable team, first-class facilities, access to human bio-samples with known clinical histories as well as their hospital partners, and most importantly, their shared passion to identify and help to develop predictive, preventive and curative solutions for cardiovascular disease, our sole mission and focus. That WSU and their team is in our backyard is truly a blessing for us,” added Arterez CEO Mike Brennan.

###

Thanks to assistance from Mary McCardwell, project manager of the Economic Growth Institute at the University of Michigan, and the Michigan Corporate Relations Network, matching funds of $40,000 were provided for this project via the Small Company Innovation Program. An additional $190,000 will be funded directly by Arterez.

Wayne State University is one of the nation’s pre-eminent public research universities in an urban setting. Through its multidisciplinary approach to research and education, and its ongoing collaboration with government, industry and other institutions, the university seeks to enhance economic growth and improve the quality of life in the city of Detroit, state of Michigan and throughout the world. For more information about research at Wayne State University, visit http://www.research.wayne.edu.

About Arterez, LLC: Arterez is a Michigan-based biosciences company focused on the development of predictive diagnostic kits as well as a first-in-class triple compound oral therapy targeting the multi-factorial root causes of cardiovascular disease including the repair and maintenance of the Endothelial Glycocalyx, while minimizing the damaging effects of oxidation and reducing inflammation. For more information, contact Mike Brennan, [email protected] or visit https://www.arterez.com/

Media Contact
Julie O’Connor
[email protected]
313-577-8845

Tags: CardiologyCollaborationHealth CareMedicine/Health
Share12Tweet7Share2ShareShareShare1

Related Posts

STORK Test

New prenatal test can reduce time, cost of detecting chromosomal abnormalities

August 17, 2022
Three pupils studying with calculators.

Preterm birth’s link with educational attainment explored in U.K. primary and secondary schoolchildren

August 17, 2022

“Nutri-Score” label may counter misleading sugar claims on groceries

August 17, 2022

New research model illuminates how organs communicate with each other

August 17, 2022
Please login to join discussion

POPULAR NEWS

  • Picture of the horse specimen.

    Ancient DNA clarifies the early history of American colonial horses

    56 shares
    Share 22 Tweet 14
  • Fatigue, headache among top lingering symptoms months after COVID

    40 shares
    Share 16 Tweet 10
  • Ill-fated ‘Into the Wild’ adventurer was victim of unfortunate timing, Oregon State study suggests

    39 shares
    Share 16 Tweet 10
  • Skin: An additional tool for the versatile elephant trunk

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

Urogenital SystemZoology/Veterinary ScienceVaccinesUrbanizationVaccineWeather/StormsVehiclesUniversity of WashingtonViolence/CriminalsVirologyWeaponryVirus

Recent Posts

  • New model describes puffs, slugs, and the role of randomness in transitional turbulence
  • This mouse can’t keep a secret about the “secretome”
  • New prenatal test can reduce time, cost of detecting chromosomal abnormalities
  • Dogs lying in the middle of the road after sunrise at Kewa Pueblo, in no hurry to start the day
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In